Lorazepam (Elderly — Short-Term Use)
Brand names: Ativan
This page addresses short-term lorazepam use in older patients; it is a short-to-intermediate-acting benzodiazepine used briefly for severe anxiety, agitation or as an anxiolytic, where falls and confusion risks dominate.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
It enhances the inhibitory action of GABA at the GABA-A receptor, increasing chloride conductance to produce anxiolytic, sedative and anticonvulsant effects.
Prescribing in practice
- In older people benzodiazepines markedly increase the risk of sedation, confusion, cognitive impairment and falls, so use the lowest effective dose for the shortest possible time and avoid routine or prolonged use.
- Tolerance and dependence develop with continued use, so plan a short course with a clear stopping strategy and gradual withdrawal if used beyond a brief period.
- Additive central nervous system depression occurs with opioids, alcohol and other sedatives, raising the risk of excessive sedation and respiratory depression.
Monitoring
Monitor sedation, cognition, mobility and falls risk, and review the ongoing need at each opportunity to keep the course short.
Counselling the patient
- This is intended only for short-term use to limit dependence and falls.
- It can cause drowsiness and unsteadiness; take care moving about and avoid alcohol.
- Do not stop abruptly after regular use, as withdrawal effects can occur.
Evidence & guidelines
Guidance on prescribing in older adults consistently identifies benzodiazepines as high-risk for falls and cognitive harm, supporting short-term use only with a planned withdrawal.
Reference: NICE NG11; STOPP/START version 3; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- SCORE2-OP — 5/10-Year CVD Risk (Age ≥ 70) · Cardiovascular Risk
- Hearing Handicap Inventory for the Elderly — Screening (HHIE-S) · Hearing
- Clinical Frailty Scale (CFS) · Prognosis
- Confusion Assessment Method (CAM) · Cognitive Assessment
- Benzodiazepine Conversion Calculator · Drug Conversion
- Berg Balance Scale (BBS) · Rehabilitation
- Falls Assessment in Older Adults · NICE CG161 2013
- Delirium Outside ICU · NICE CG103
- Comprehensive Geriatric Assessment (CGA) · BGS / NICE
- Delirium Assessment and Management · NICE CG103 2010
- Frailty Recognition and Management · BGS Frailty Framework / NHS NHSE
- Polypharmacy and Medicines Optimisation · STOPP/START v2 2014 / NICE NG5